GoodRx BusIntell Report

GoodRx is building the leading, consumer-focused digital healthcare platform in the United States. GoodRx provides easy access to price transparency and affordability solutions for medications, convenient telehealth consultations, and additional healthcare services and resources.

GoodRx was founded in 2011 and has been publicly traded since September 2020. The company believes its offerings help drive greater medication adherence, faster treatment, and better patient outcomes.

GoodRx, with almost 1,000 employees, sees growth potential as it continues to attract new consumers through its existing offerings, launches new offerings to address more of the needs of healthcare consumers, and improves healthcare affordability and access for all Americans. GoodRx’s unique, proprietary and extensible platform has now saved consumers a cumulative $40 billion.

GoodRx’s rapid growth has recently slowed as it expects 2022 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable portion of its grocery prescription business. GoodRx disclosed that it is unlikely to achieve its full-year 2022 guidance after a grocery chain stopped accepting discounts for certain drugs.

During the first quarter of 2022, despite the company’s announcement of the impact of a grocery store partner, revenue and adjusted EBITDA were both ahead of expectations  primarily due to the growth of the company’s pharmaceutical manufacturer solutions offering, which was further supported by the continued strength of GoodRx’s prescription-related offerings, both prescription transactions and subscriptions.

GoodRx provides solutions across the healthcare journey with its offerings, including GoodRxHealth, Prescription Savings, Subscriptions, Pharmaceutical Manufacturer Solutions, and TeleHealth.

AMI’s GoodRx BusIntell Report provides a comprehensive study on the company and its impact on prescription savings and relationships with patients, payers and PBMs.

Table of Contents

• Background – pgs. 4-6
• Executives – pg. 7
• Strategy – pgs. 8-9
• Strengths – pg. 10
• Weaknesses – pg. 11
• Financial and Statistical Information – pgs. 12-15
• Products and Services – pgs. 16-21
  • Prescription Transactions Offering
  • Subscription Offerings
  • Pharma Manufacturer Solutions Offering
  • TeleHealth Offering
• Company Activities – pgs. 22-23